Videos

Martin Dreyling, MD, discusses the final follow-up results of the TRIANGLE study in mantle cell lymphoma.

Jacob E. Berchuck, MD, discusses how a new epigenomic platform may influence the accessibility of PSMA-based therapies, especially for patients who may not have easy access to PSMA PET scans.

Panelist discusses how there are many significant attributes of the bispecific antibody, which has broader applicability and can be used in widespread community centers. There are more community centers that are staring to use bispecific antibodies, and there is now a much lower rate of CRS and immune effector cell–associated neurotoxicity syndrome (ICANS).

Hope S. Rugo, MD, FASCO, discusses the role of abemaciclib plus elacestrant for ER+/HER2– MBC from data presented at SABCS 2024.

Panelists discuss key takeaways from the COMMANDS trial, including the analysis of biomarkers in responders by ribosomal stress status (Hayati et al, EHA 2024), the impact of luspatercept on cell lineages (Garcia-Manero et al, EHA 2024), and the long-term clinical value of extended RBC transfusion independence (RBC-TI) (Garcia-Manero et al, ASH 2024).

Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk myelodysplastic syndrome (LR-MDS), with particular consideration of ribosomal stress (RS) status and serum erythropoietin (EPO) levels, emphasizing its potential to improve hemoglobin levels and transfusion independence in this patient population.

A panelist discusses how the phase 2 ELECTRA trial studies elacestrant in combination with ribociclib as first-line therapy for ER+/HER2– advanced breast cancer in postmenopausal women.

Sanjay K. Juneja, MD, discusses how artificial intelligence is transforming early cancer screening.

Mark Agulnik, MD, discusses the intricacies of desmoid tumors that can be recognized before starting treatment for patients.

Dr. Joshua Sabari discusses the impact that identification of common and rare actionable alterations has had on personalized therapy selection and improved outcomes for patients with NSCLC.

A panelist discusses how managing relapsed/refractory follicular lymphoma (R/R FL) requires carefully weighing multiple factors including patient fitness, prior therapies, duration of response, symptoms, and treatment goals while confronting challenges like treatment resistance, cumulative toxicities, and the lack of a clear standard of care sequence.

Sanjay K. Juneja, MD, discusses how artificial intelligence has evolved in 2024 to help improve early detection of cancer.

Eunice S. Wang, MD, discusses the role of transplant eligibility in shaping treatment strategies for secondary acute myeloid leukemia.

Experts review the 5-year results of the phase 3 SEQUOIA trial evaluating treatment options for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma at the 66th American Society of Hematology Annual Meeting and Exposition 2024.

A panelist discusses how EGFR-mutated NSCLC treatment has evolved to include multiple generations of EGFR tyrosine kinase inhibitors as first-line therapy, with newer agents showing improved efficacy compared with earlier options.

Thomas W. LeBlanc, MD, MA, discusses how the standard of care (SOC) options for anemia management in patients with low-risk myelodysplastic syndromes (LR-MDS) typically involve erythropoiesis-stimulating agents and transfusion support, with emerging therapies like luspatercept offering new treatment options for better patient outcomes.

Chunhui Han, PhD, discusses the use of of Gallium 68 PSMA-11 in biology-guided radiotherapy and whether or not the radiotracer can improve the targeting and treatment of bony metastases in patients with prostate cancer.

Aimee Merino, MD, discusses how the treatment decision for a 60-year-old patient with early relapse/refractory multiple myeloma, involving chimeric antigen receptor (CAR) T-cell therapy, aligns with the goals of therapy while exploring alternative treatment options and considerations for high-risk patients.

Panelist discusses how pivotal studies led to the approval of teclistamab in patients with less refractory multiple myeloma; the overall response rate was 63% and the progression of survival rate was 11.3 months.

Panelist discusses how, based on the patient achieving sCR with emerging oral, skin, and nail toxicities, panelist would recommend initiating supportive care, including oral hygiene protocols, topical treatments, and prophylactic nail care. These toxicities are generally less severe than those of BCMA-targeted bispecifics, which often present with more systemic CRS and neurotoxicity.

Samer A. Al’Hadidi, MD, discusses the follow-up data for ciltacabtagene autoleucel in patients with multiple myeloma.

Luis E. Raez, MD, discusses the current liquid biopsy options for patients with lung cancer through assessing circulating tumor DNA.

James J. Harding, MD, provides a high-level overview of systemic therapy for untreated unresectable hepatocellular carcinoma (uHCC) based on NCCN Guidelines, and discusses the evolving treatment landscape, including the rationale for combination immunotherapy (IO) and how additional IO combinations may address unmet needs like depth of response and resistance.

Petros Grivas, MD, PhD, discusses the key trials of bladder cancer using immunotherapy he highlighted during a Case-Based Roundtable event.

Eunice S. Wang, MD, discusses research behind optimal therapy for acute myeloid leukemia secondary to other malignancies, particularly in patients with prior myelodysplastic syndrome.

Alexa Simon Meara, MD, discusses the importance of including a rheumatology approach to immunotherapy treatment for cancer.

Panelists discuss how recent therapeutic advances, including novel drug combinations and personalized treatment approaches, are reshaping the standard of care for patients with newly diagnosed multiple myeloma (NDMM) while emphasizing the importance of risk stratification and early intervention strategies.

With the Oncology Brothers, Uma Borate, MD, discusses how the combination of venetoclax with an IDH1 inhibitor and 7+3 chemotherapy leads to higher remission rates and MRD negativity in IDH1-mutated AML, offering a promising treatment option for these patients.

With the Oncology Brothers, Uma Borate, MD, discusses how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in treating acute myeloid leukemia with mutations in measurable residual disease (AML-MR) by specifically targeting the genetic mutations driving the disease, leading to improved patient outcomes.

With the Oncology Brothers, Uma Borate, MD, discusses how ziftomenib is showing promising results as a targeted therapy for NPM1-mutated and KMT2A-rearranged acute myeloid leukemia (AML) in the ongoing KOMET-007 trial, offering potential new treatment options for this challenging patient population.